Opendata, web and dolomites

TinniMizer

TinniMizer : A Patient-specific Novel Approach for Tinnitus Treatment

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "TinniMizer" data sheet

The following table provides information about the project.

Coordinator
GENMEL BIYOMEDIKAL TEKNOLOJI ARGE SANAYI VE TICARET LIMITED SIRKETI 

Organization address
address: CIFTEHAVUZLAR MAH. ESKI LONDRA ASFALTI CAD. KULUCK ERC1 BLOK 151/1E/105
city: ISTANBUL
postcode: 34220
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Turkey [TR]
 Project website http://www.genmel.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GENMEL BIYOMEDIKAL TEKNOLOJI ARGE SANAYI VE TICARET LIMITED SIRKETI TR (ISTANBUL) coordinator 50˙000.00

Map

 Project objective

Tinnitus can be a debilitating condition, which negatively affects a patient’s overall health and social well-being. Even moderate cases can interfere with the ability to work and socialise. The financial consequences of tinnitus are significant. Personal economic loss to an individual with tinnitus--including lost earnings, productivity, and health expenses--can be up to €30,000 annually. The cost to society as a whole has been estimated at upwards of €26 billion annually. Despite these effects there is currently no scientifically proven cure for most cases of chronic tinnitus. The medical doctors (ENT specialists), audiologists, and electronics-biomedical engineers in Genmel Technology have developed a new, patient-specific, state-of-the-art, and patented musical therapy system called TinniMizer as a new treatment for Tinnitus due to a substantial need to cure the tinnitus with an easy-to-use and cost-effective therapeutic system. Preliminary results obtained from about 20 patients at three clinics (Tinnitus Treatment Centers) indicate that after using TinniMizer system for about 3 months, there is approximately 70% reduction in the complaints of tinnitus patients. Through this project, Genmel will further develop this therapy to result in over 95% reduction in tinnitus. In other sound therapy systems, the duration of therapy is 1.5 years. Our goal is to reduce this period to a much shorter period (up to 3 months). Genmel offers R&D solutions, productions, and consulting services especially in the field of Biomedical, Electronics, Medicine and Energy. Academicians, engineers and technicians are working in GENMEL. The main goal of GENMEL is to develop and bring to market new products, services and business models that could drive economic growth. Through this project, Genmel aims to achieve a total turnover of >€14.5 million by the 5th year of TinniMizer commercialization.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TINNIMIZER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TINNIMIZER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More  

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

ALICE (2019)

Armored Liftable anti-Intrusion Control Equipment

Read More